Biohaven Taking Troriluzole Into Phase III OCD Study Despite Phase II/III Miss
Executive Summary
After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.
You may also be interested in...
Biohaven’s Life Without CGRP Inhibitors Gets Off To A Rocky Start
With the sale of its migraine portfolio to Pfizer pending, Biohaven said troriluzole – a lead asset in the pipeline soon to be spun out in a new company – failed in a Phase III trial.
Biohaven Faces Another Pipeline Upset, But Focus Remains On Migraine Portfolio
The company, which has reported no R&D successes outside of its CGRP inhibitor platform, said verdiperstat did not differentiate from placebo on any endpoints in multiple system atrophy.
With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next
The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.